FDA approves Pfizer drug Crisaborole for atopic dermatitis

FDA approves Pfizer drug Crisaborole for atopic dermatitis

The U.S. Food & Drug Administration (FDA) on Wednesday approved the topical drug crisaborole for the treatment of mild to moderate itchy skin condition eczema or atopic dermatitis in patients aged two years and older.

Atopic dermatitis is a chronic inflammatory skin disease that causes red, flaking and crusted bumps on the patient's skin that are often extremely itchy.

Crisaborole, a Pfizer Inc. ointment to treat the itchy skin condition, will be sold under the brand name Eucrisa. Many health experts consider atopic dermatitis as a large market with an unmet need.

Amy Egan, the deputy director of the Office of Drug Evaluation III in the federal agency's Center for Drug Evaluation & Research, said, "Today's approval provides another treatment option for patients dealing with mild to moderate atopic dermatitis."

Pfizer acquired the drug through its $5.2 billion acquisition of Anacor Pharmaceuticals earlier in 2016. Eucrisa will be available with a wholesale price tag of $580 for a 60 gram tube. The company has pegged annual sales for the drug at an estimated $2 billion.

Stock in Pfizer Inc. was little changed following the announcement of FDA's approval for the ointment, closing at $32.82 per share on the New York Stock Exchange.



Whether you want to ask us a question, would like to solve a problem, or just give us a suggestion, you’ll find many ways to contact us right here.

Email: editor@norcal.news

Phone: (916) 225-9835

Fax: (916) 225-9845


Subscribe and get the latest updates, news and more...